Sci Rep:晚期前列腺癌血浆中雄激素受体和血清嗜铬粒蛋白A研究

2018-10-29 AlexYang MedSci原创

最近,前列腺腺癌和神经内分泌前列腺癌(NEPC)的混合形式出现,并且可以通过持续的雄激素受体(AR)信号和提高的血清嗜铬粒蛋白A(CgA)水平来鉴定。有研究人员对阿比特龙或恩杂鲁胺治疗的去势难治性前列腺癌(CRPC)患者进行了分析,并且评估了无进展/总生存(PFS/OS)以及相关的循环AR和CgA情况。研究人员利用液滴数字PCR对AR的变化进行了分析,样本是来源于2个生物标记筛选群体的预处理血浆样

最近,前列腺腺癌和神经内分泌前列腺癌(NEPC)的混合形式出现,并且可以通过持续的雄激素受体(AR)信号和提高的血清嗜铬粒蛋白A(CgA)水平来鉴定。有研究人员对阿比特龙或恩杂鲁胺治疗的去势难治性前列腺癌(CRPC)患者进行了分析,并且评估了无进展/总生存(PFS/OS)以及相关的循环AR和CgA情况。

研究人员利用液滴数字PCR对AR的变化进行了分析,样本是来源于2个生物标记筛选群体的预处理血浆样本(197名来自一个回顾性研究(REC2192/2013);59名来自一个前瞻性研究(REC 6798/2015))。研究人员根据ROC曲线的CgA将患者分成3个组。在主要群体中,血浆AR的获得和变异(p.L702H/p.T878A)分别在78(39.6%)和16(8.1%)名患者中检测到。研究人员在具有更高CgA的患者中观察到了PFS/OS比正常CgA明显更差的情况,尤其是在那些没有AR异常的参与者中。多变量分析表明,AR获得、更高的CgA和LDH水平是PFS(分别为:HR=2.16,95% 置信区间(95% CI) 1.50-3.12, p<0.0001,;HR=1.73, 95% CI 1.06-2.84, p=0.026和HR=2.13, 95% CI 1.45-3.13, p=0.0001)和OS(分别为:HR=1.72, 95% CI 1.15-2.57, p=0.008, HR=3.63, 95% CI 2.13-6.20, p<0.0001和HR=2.31, 95% CI 1.54-3.48, p<0.0001)的独立预测因子。上述结果在一个次级群体中进一步得到了确定。

最后,研究人员指出,治疗前CgA检测在鉴定那些具有混合肿瘤的患者中是有用的,并且具有预后的作用,尤其是那些AR正常的患者中。另外,研究人员也指出,上述相关性需要在更大的前瞻性群体中进行进一步的评估。

原始出处:

Vincenza Conteduca, Emanuela Scarpi, Samanta Salvi et.al. Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. Sci Rep. 18 Oct 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953507, encodeId=1614195350e10, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Nov 27 15:12:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350542, encodeId=0f24135054272, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Oct 31 04:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412781, encodeId=da861412e81c2, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 31 04:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1953507, encodeId=1614195350e10, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Nov 27 15:12:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350542, encodeId=0f24135054272, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Oct 31 04:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412781, encodeId=da861412e81c2, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 31 04:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1953507, encodeId=1614195350e10, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Nov 27 15:12:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350542, encodeId=0f24135054272, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Oct 31 04:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412781, encodeId=da861412e81c2, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 31 04:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=)]